Los Angeles Capital Management’s Acorda Therapeutics ACOR Stock Holding History

Los Angeles Capital Management’s Portfolio ACOR Stock Details ACOR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-137	Closed	-$322K	–	1413
2018 Q3	$322K	Hold	137	–	–	﹤0.01%	1206
2018 Q2	$471K	Sell	137 -373	-73%	-$1.14M	﹤0.01%	1152
2018 Q1	$1.45M	Buy	510 +164	+47%	+$491K	0.01%	730
2017 Q4	$890K	Buy	+346	New	+$984K	﹤0.01%	882
2016 Q3	–	Sell	-82	Closed	-$251K	–	1299
2016 Q2	$251K	Buy	+82	New	+$267K	﹤0.01%	1102
2016 Q1	–	Sell	-81	Closed	-$414K	–	1209
2015 Q4	$414K	Sell	81 -18	-18%	-$78.7K	﹤0.01%	900
2015 Q3	$315K	Hold	99	–	–	﹤0.01%	1000
2015 Q2	$396K	Sell	99 -30	-23%	-$116K	﹤0.01%	991
2015 Q1	$516K	Buy	+129	New	+$591K	﹤0.01%	918

Other funds holding ACOR

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Los Angeles Capital Management's ACOR Position: Q4 2018 in Review

Los Angeles Capital Management sold out of Acorda Therapeutics (ACOR) in Q4 2018, closing a stake of 137 shares — an estimated $322K sold.

Los Angeles Capital Management first reported a position in ACOR in Q1 2015 and held it in 9 quarters. The position peaked at $1.45M in Q1 2018. 179 funds tracked by Wall St. Rank hold ACOR as of Q4 2018.

Los Angeles Capital Management reported no remaining Acorda Therapeutics position as of Q4 2018 after selling out during the quarter.
Los Angeles Capital Management sold 137 Acorda Therapeutics shares in Q4 2018, an estimated $322K.
Los Angeles Capital Management first reported a position in Acorda Therapeutics in Q1 2015 and held it in 9 quarters.
Los Angeles Capital Management's Acorda Therapeutics position peaked at $1.45M in Q1 2018.
179 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2018.

Based on Los Angeles Capital Management's 13F filing for Q4 2018, filed 11 Feb 2019.